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r e v i e w article

Practical and predictive bioinformatics methods for the
identification of potentially cross-reactive protein matches
Richard E. Goodman
Food Allergy Research and Resource Program, Department of Food Science & Technology, University of
Nebraska–Lincoln, Lincoln, Nebraska, USA; email rgoodman2@unl.edu
Abstract
A bioinformatics comparison of proteins introduced into food crops through genetic engineering provides a mechanism to identify those proteins that may present an increased risk of allergic reactions for individuals with existing
allergies. The goal is to identify proteins that are known to be allergens or are so similar to an allergen that they
may induce allergic cross-reactions. Three comparative approaches have traditionally been used, or considered for
safety evaluations. One identifies any short (6–8) amino acid segment of the protein that exactly matches a known
allergen sequence. The second is an overall primary sequence comparison using Basic Local Alignment Search
Tool (BLAST) or FASTA to find matches of greater than 35% identity over 80 amino acids. The third is based on 3-D
prediction programs to identify 3-D similarities that might predict potential cross-reactivity. The utility of each of
these approaches was debated in the bioinformatics workshop. The consensus agreement from the expert workshop participants was that the short-segment match (e.g., 6–8 amino acids) provides an unacceptably high rate of
false positive matches and an uncertain rate of true positive matches, and was not particularly useful for an allergenicity evaluation performed in the context of comprehensive safety evaluation. There was no consensus regarding the most appropriate bioinformatics method, an acceptable scoring criteria for triggering closer examination
subsequent to a positive match, or an acceptable scoring mechanism for ranking the utility of the various 3-D approaches that were discussed during the workshop. However, the general consensus was that the most practical
approach at this time is to evaluate primary sequence identities to known allergens using either FASTA or BLAST.
While there was good agreement that identities of greater than 35% over 80 or more amino acids (recommended
by Codex in 2003) is quite conservative, the conclusion was that additional data or studies would be needed to
justify changing this criterion as there is some evidence that some individuals sensitized to proteins in evolutionarily conserved protein families may experience cross-reactions to proteins sharing approximately 40% identity.
Keywords: Allergen, Conformational epitope, Discontinuous epitope, Epitope, IgE
Abbreviations: BLAST, Basic Local Alignment Search Tool; GE, genetic engineering;
FAO/WHO, Food and Agriculture Organization/World Health Organization

1 Introduction

countries have now implemented requirements for evaluating the potential allergenicity of such products [1]. The
primary focus, either elaborated or implied, is on preventing the transfer of a known allergen, or a protein sufficiently
similar to a known allergen that it may trigger allergic crossreactions. Specific methods are used to reduce the possibility of transferring an allergen or cross-reactive protein.
One of the most informative tests is the use of computer

Genetic engineering (GE) and food processing methods are
both being used to introduce specific beneficial proteins
into foods and consumer products. Regulatory bodies in
various countries differ in their requirements for evaluating
the safety or potential risks of products that include these
newly introduced proteins. The US, EU, and many other
655
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programs to compare the amino acid sequence of the introduced protein with those of known allergens. Any significant resulting matches to a known allergen are used to
identify a group of potentially at-risk individuals who could
be tested to evaluate potential clinical risks by serum testing, skin prick testing, or even food challenge. The use of
an effective system of comparison is important for the success of the allergenicity assessment.
The ideal situation for the allergenicity prediction would
be to determine whether all biologically important IgE-binding epitopes were known for all of the major allergens, and
if computer programs could predict biologically important
similarities between a new protein and the epitopes of an
allergen. Unfortunately, very few epitopes have been thoroughly mapped for even a few allergens using sera from representative allergic populations. Furthermore, while IgE epitopes may consist of short-sequential amino acid segments,
in some cases they are formed by 3-D structures produced
by the arrangement amino acids that are spatially close due
to protein folding, and are therefore called discontinuous
epitopes [2]. Even for some of the most highly studied allergens, close evaluation of the sequences and 3-D structures
have demonstrated variability between epitopes recognized
by individuals or between apparent cross-reactive structures
that are not perfectly conserved or predictable [3, 4]. What
we do know about many important allergens and even minor
allergens is the primary (amino acid) sequence of the protein.
Therefore, the evaluation of protein sequence and structure
have focused on the use of general local sequence alignment
algorithms such as FASTA or Basic Local Alignment Search
Tool (BLASTP) that are frequently used in academic research
to efficiently identify sequences from related species that are
likely to be homologous. Empirical results demonstrate that
proteins that are closely matched in sequence have similar
structure and the most highly similar protein matches found
with these programs often correspond to antibody cross-reactivity and clinical reactivity [5].
On the basis of scientific data available in the early 1990s,
the first widely published comprehensive recommendation
for evaluating the potential allergenicity of genetically engineered crops suggested performing a local alignment by
FASTA or BLASTP to identify probable homologs and then
identify any exact matches of eight contiguous amino acids shared between the query sequence (GE protein) and
any allergen [6]. Scoring parameters (gap penalties, mismatch penalties, etc.) of both FASTA and BLAST programs
can be modified so that results can differ markedly. While
there are generally accepted default criteria used by either
program to identify probable homologs, those criteria were
not specified by Metcalfe et al. [6]. Furthermore, there has
not been a generally recognized level of identity between

two proteins that is considered “significant” in regard to
the potential for cross-reactivity. As explained in the original publication, the criterion of an eight amino acid match
was meant to identify potentially shared IgE or T-cell epitopes [6]. However, questions have been raised by many authors about the possibility of missing important matches
using this criterion [7, 8]. The Food and Agriculture Organization/World Health Organization (FAO/WHO) 2001 scientific panel recommended a dual test, one looking for any
match of six contiguous amino acids, the second looking for
identity matches above 35% over any 80 amino acid segment of the query protein compared to any known allergen. The predictive value of an eight amino acid match, or
even smaller matching segments such as six, however, had
not been tested in published studies until around 2002.
The FAO/WHO panel report stimulated a number of efforts
as reported in three studies that demonstrated that more
appropriate criteria are needed. Hileman et al. [9] found
that roughly 80% of randomly chosen protein sequences of
maize match an allergen if a six amino acid match is used,
while comparisons for eight amino acid matches or those
with >35% identity over 80 amino acids were more accurate in identifying proteins with overall FASTA alignments
that would indicate an increased potential for shared sequential and conformational epitopes. Kleter and Peijnenburg [8] found also that six amino acid matches also identify
matches unlikely to cause cross-reactions, and they investigated using a subsequent evaluation for antigenicity prediction for any matched proteins.
There have also been suggestions that structural comparisons or motif recognition patterns would provide better
predictions for evaluating the potential allergenicity of novel
proteins [10, 11]. But to date, these methods have generally
not been used to evaluate a wide range of proteins in the
context of the allergenicity assessment.
As the sequence comparison, or bioinformatics, is a very
important part of the safety assessment process for genetically engineered crops, and significant questions have been
raised about the best methods to perform such tests, the International Life Sciences Institute–Health and Environmental
Sciences Institute sponsored a scientific workshop in Mallorca, Spain in February 2005 to address these questions. Participating scientists included a broad spectrum of experts in
bioinformatics, food safety, and allergy/allergenicity.
This chapter will provide a brief description of bioinformatics methods that have been used, or proposed for regulatory studies evaluating proteins from genetically engineered crops that were discussed at the meeting. Key points
of the discussion will be reviewed, and the points of consensus or majority opinions voiced by the experts will be
presented.
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2 Allergen databases
Allergen specific sequence databases [12] are very useful
for improving the efficiency of the computerized sequence
comparisons to identify potentially cross-reactive allergens,
in contrast to searches using a more generalized sequence
database such as NCBI or Swiss-Prot. A general database
screen would require significantly more manual data analysis
of identified matches in order to evaluate the allergenicity of
the matched sequences. In 1996, public allergen databases
were not available on the internet. Researchers could compile their own list from GenBank or Swiss-Prot by searching
protein or cDNA sequences with query terms such as “allergen.” Now several databases of allergens — e.g., Allergenonline: http://allergenonline.com — are available on the internet and can be queried with the amino acid sequence of any
protein. Additionally, 3-D or structural data are available for
a few of the most studied allergens. The focus of this paper
is on the methods that can be used to compare a sequence
to the database to evaluate the similarity of any protein to
known or putative allergens.
Two cautions are in order regarding ”allergens” in any database. First, even the most carefully curated database will
have a number of proteins included for which there is little
objective evidence for allergenicity, and conversely, all will
miss a few allergens. Second, the range of potencies, or incidence of allergy associated with various proven allergens
is wide, as is the potential reactivity if the protein is presented in food, or via the airway. These factors should be
kept in mind when considering the potential risk of allergy
from an introduced protein having a sequence that matches
any allergen.

3 Short contiguous amino acid matches
The practice of searching for identical short amino acid
matches between the introduced GE protein and sequences
from known allergens had not been evaluated in terms of
efficiency until recently [9, 10]. However, short peptide sequence matches have been used to evaluate most, if not all,
of the proteins introduced into commercially available GE
crops that have been reviewed by US, Japan and EU regulators. Summary safety data for a number of GE products are
available online: http://usbiotechreg.nbii.gov/database_ pub.
asp ; http://www.agbios.com/dbase.php . The original recommendation [6] suggested first aligning the query protein (introduced GE protein) with any known allergen be performed
using FASTA or BLAST and the resulting alignments of presumably homologous sequences be evaluated for any identical eight amino acid match. Such a match was thought to
indicate that the GE protein might cause cross-reactions in
those allergic to the matched allergen as proteins having an
overall alignment which suggests overall structural similarity
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and evolutionary divergence, which also has significant short
sequence matches, may have a higher probability of sharing
IgE epitopes. However, in practice, these searches have been
performed using simple algorithms that were developed to
find identical strings, or words, much like the search function of a word processing program [9]. Each individual possible contiguous amino acid sequence segment of the protein
was used to search a selected allergen database for an exact
match. The first search cycle would compare amino acids one
to eight of the query to the database, the second cycle would
query amino acids two to nine. The process would continue
until the final eight amino acid segment is tested. Currently,
there are at least two websites — Allermatch: http://allermatch.org and the Structural Database of Allergenic Proteins,
SDAP: http://fermi.utmb.edu/SDAP/ — that provide shortsegment (6 or 8 amino acids) matching algorithms. However,
since these procedures do not first screen for potential homology, the results may be significantly different than anticipated by the original authors [6]. When direct string matches
have been performed, it is clear from the high number of
matches using common protein sequences that this method
greatly overestimates probable allergenic matches [9]. The
data demonstrate that the high false positive rate observed
with six or seven amino acid matches is unacceptable and
that the eight amino acid matches may be irrelevant. There
are no clear data to demonstrate that this approach adds
value over a properly performed local sequence alignment.

4 Local alignments with FASTA or BLASTP
FASTA [13] and BLAST [14] are computer algorithms that
were written to provide efficient computer comparisons of
nucleic acid or protein sequences derived from distantly related organisms. The algorithms scan each sequence in a
database using the query sequence to identify short “seed”
matches. If a minimal match is found, the sequence match
is optimized to provide a best overall match for that sequence. As the entire database is scanned, a list is formed
with the best matches at the top. Available scoring matrices
that may be selected for use by the algorithm (BLOSUM 50,
PAM 62, PAM 250, etc.) were developed with biases toward
more (or less) conservation of structure based on structurally dominant amino acids (e.g., proline, tyrosine, phenylalanine) and frequencies of occurrence. Additional scoring factors such as gap extension penalties (corrections for
the insertion of an artificial gap in a sequence, to optimize
the alignment) will alter the alignment and scores. The default settings for FASTA run on Allergenonline are BLOSUM
50, with ktup (seed word size) of 2, gap penalty of –10, and
gap extension penalty of –2. The resulting Z score is converted into an E score that includes a correction for database size and complexity. The smaller the E score the more
similar two sequences are, and the greater the likelihood
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they share overall structure and evolutionary heritage. In
general, an E score value less than 0.02 indicates probable homology [15]. However, based on experience, E scores
between 10–2 and 10–7 are relatively common between protein sequences that are evolutionarily related, but do not
share histories of allergic cross-reactivity [9]. Since E scores
will vary with the size of the database, and scoring matrices (e.g., vicilin of walnut, GI 6580762 matches lentil allergen Len c 1, GI 29539109 with an E score of 4.3 × 10–11 using FASTA with Allergenonline version 5.0, but the E score
using BLAST with NCBI results in an E score of 9 × 10–82),
while percentage identities are constant (39% identity over
410 amino acid alignment for the same alignment of walnut
and lentil proteins), it is reasonable to simply evaluate the
E score for any match to decide whether the query protein
sequence represents a close homologue of any allergen.
What value of shared identity might represent a realistic risk of cross-reactivity? Pearson [15], who developed the
FASTA algorithm, observed that proteins that are apparently
quite distantly related through evolution may share as little
as 20–25% identity over the majority of the length of the encoded polypeptides and still be considered homologs. These
proteins will usually share common structural folds and either similar or related functions. However, Pearson [15] also
noted that two quite distinct proteins that do not share overall structure or function may by chance share 50% identity
over a segment of 20–40 amino acids.
Aalberse [16] observed that it is rare to find true clinical
cross-reactivity in a single patient if proteins share less than
50% identity over their full-lengths, while proteins sharing greater than 70% identity are commonly cross-reactive. At the same time, the FAO/WHO expert panel recommended that an identity greater than 35% over 80 or more
amino acids should be used as a guideline to suggest possible cross-reactivity (Food and Agriculture Organization of
the United Nations. FAO Corporate Document Repository.
http://www.fao.org/documents/show_cdr.asp?url_file=/docrep/007/y0820e/y0820e00.htm ). Some very elegant studies
have been performed that evaluate the relationship between
clinical reactivity, in vitro binding, and histamine release of
homologous allergens that span a wide range of sequence
identity [5]. Those studies have shown marked reduction in
IgE binding of 100–1000-fold for proteins sharing only ~40%
identity. However, the examples may overestimate true crossreactivity because individuals are exposed to related allergens and may be sensitized to one or more of the related
homologs [17, 18]. Few other detailed studies have been performed to evaluate the relationship between cross-reactivity and sequence or structural similarity with a quantitative
measurement of binding efficacy.
While some may argue in favor of adjusting (or not) the
criteria of similarity matches with 35% identity over 80 amino

acids, it is important to recognize that a match of greater
than 50% to 70% identity over the full-length of two proteins
is much more likely to indicate potential in vitro cross-reactivity and/or clinical relevance. Although the direct proof of
clinical cross-reactivity is nearly impossible to obtain, there
are many studies that demonstrate the positive correlation
between percent identity and likelihood of in vitro IgE binding and clinical reactivity. For example, Beyer et al. [19] found
that while 12 of 14 hazelnut allergic individuals had serum
IgE that bound to the 11S hazelnut globulin, only about onehalf experienced any clinical reactivity to the relatively unrelated peanut, walnut, brazil nut, cashew nut, or almond, and
only one of those experienced reactions to more than two.
This lack of clinical reactivity occurs despite the fact that the
11S globulins that have been sequenced from that group
(hazelnut, peanut, brazil nut, cashew) share between 45 and
55% identity. Since the 11S albumins are major seed storage
proteins, they would all be expected to share clinical symptoms if 45–55% identity was likely to indicate cross-reactivity. Sanchez-Monge et al. [20] found that 18 of 18 individuals with allergies to garden peas are also allergic to lentils.
They identified two related pea proteins, vicilin and convicilin, and fragments thereof, which appear responsible for essentially all IgE reactivity in pea extract. Pea and lentil vicilins
are ~90% identical, the two convicilins are over 70% identical and within each species, vicilin and convicilin share approximately 60% identity.
Based on the current evidence, as well as the general observations of Aalberse [16], matches of greater than 50%
identity by FASTA or BLAST should be evaluated very closely
to determine whether a protein of interest may lead to crossreactions in individuals with existing allergies, while a match
of less than 35–40% identity is likely to represent a much
lower probability of cross-reactivity. Further scientific evaluation of this issue will likely require specific in vitro IgE-binding studies using well-characterized sera from individuals allergic to the matched allergen. The data suggests that 35%
identity over 80 amino acids represents a very conservative
limit for triggering further examination. In fact, this limit may
be much lower than necessary to still protect most allergic
individuals from the introduction of a cross-reactive protein.
However, additional data from well-controlled studies would
likely be required to justify raising the limit above 35% identity over 80 amino acids.

5 Structural comparisons
As the 3-D structure of more allergens have been either directly (X-ray crystallography or NMR) or indirectly (computer
prediction) analyzed and compared, it is clear that many important allergens can be grouped into a small number of
structural families [21]. This implies that the structural folds
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of proteins within the family are similar. IgE binding to many
allergens is conformational, meaning the epitope may be
comprised of amino acids that are not adjacent in primary sequence. Structurally similar proteins are likely to share conformational epitopes. Since primary structure (sequence) is an
essential determinant for secondary structure, and secondary
structure can alter the fine-positioning of the side-groups of
amino acids in nonlinear epitopes, the ability of a given IgE
antibody to bind to any region on a protein may be altered
by the surrounding protein structure. Therefore, one could
argue that the most appropriate way to evaluate potential
cross-reactivity would include a comparison of 3-D structures.
There are various programs and approaches that could be
used to evaluate the 3-D structure of a protein, given the primary structure [10, 11, 21]. The size, hydrophobicity, polarity,
and charge of the side-groups of each amino acid contributes to the 3-D structure. Adjacent and even relatively distant amino acids in the primary sequence will interact to influence the final protein shape. One can imagine that various
factors and methods are used by different programs to predict overall and fine-structures of proteins, but in all cases
the primary amino acid sequence plays an important role in
establishing the structure. The local environment (solvent,
pH, salt) can alter the overall shape. Some structural prediction programs evaluate similarities in the overall sequences
of proteins for specific secondary structures (e.g., likely disulfide bonds, alpha helices, turns) that are likely to dominate
secondary shape and may represent an antibody epitope.
Others focus on segments of the full-sequence, predicting
local structures independent of the overall structure or they
predict the overall structure and plot surface exposure [22].
For selected cross-reactive pairs of allergenic proteins, one
or more of these structural prediction algorithms is likely to
be highly predictive for estimating potential cross-reactivity. However, there do not appear to be any uniform measurements of similarity that have been identified to predict
probable cross-reactivity over a widely divergent set of proteins. No one has published a measurement analogous to a
percent identity (over the full-length, or even specified segment), that is quantifiable and tested on a diverse set of proteins that are known to be cross-reactive or not cross-reactive. In the future, it may be possible to develop a unified
3–D prediction tool and criteria that would be useful for predicting potential cross-reactivity; however, further evaluation
and additional data are needed to determine the feasibility
of such an approach.

6 Consensus and summary
The participants at the bioinformatics workshop in Mallorca
represented a wide range of scientific expertise in bioinformatics, structural biochemistry, allergy, immunology, food
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science, and food safety regulations. A number of participants had previously been involved in assessing the potential allergenicity of GE crops either as a reviewer, a producer, a
regulator, or an expert advisor to FAO/WHO or some country.
Discussions happened throughout the workshop about the
predictive power of various sequence and structural comparison methods. New data were presented relative to the high
incidence of randomly selected short amino acid sequences
[23]. Therefore, a formal question was posed to all regarding whether there is a useful predictive value in continuing
to perform a short, six, seven, or eight amino acid sequence
match. There was agreement that searches for short matches
are not predictive and should not be used to evaluate the potential allergenicity of proteins.
There was apparent agreement that structural comparisons may be very useful for evaluating the cross-reactivity
of two proteins, and predicting changes that might alter antibody binding. However, much of these data were apparently obtained from allergens for which some of the IgE epitopes have already been mapped. It was not clear, however,
whether these methods would be predictive for proteins that
are not highly similar in overall sequence identity. There was
a vigorous debate as to which approach would be most predictive or whether any have the ability to predict potential
cross-reactivity for proteins that are not closely related to a
known allergen. There was also a lack of clarity about how
structural similarities might be scored to provide guidance
for the safety assessment.
There was agreement among workshop participants that
FASTA or BLAST algorithms comparing a query sequence to
those of known allergens is an efficient way to identify proteins that should be studied further for potential cross-reactivity. There was sufficient debate to conclude that there is
currently not enough data to change (i.e., increase) the recommended guideline (i.e., greater than 35% identity over any
segment of 80 or more amino acids to any allergen requires
additional testing with human serum (Food and Agriculture
Organization of the United Nations, FAO Corporate Document Repository, http://www.fao.org/documents/show_cdr.
asp?url_file=/docrep/007/y0820e/y0820e00.htm ; and Codex
Alimentarius Commission, 2003, Food and Agriculture Organization of the United Nations, FAO Corporate Document
Repository, http://www.fao.org/documents ). While a number of scientists pointed out examples where proteins with
50% identity had not been shown to cause in vitro or in vivo
cross-reactions, there were a few examples where proteins
of approximately 40% identity shared some degree of in vitro cross-reactivity that correlated with clinical reactions to
the sources of those allergens. However, it was also argued
that in at least some cases, the individuals might have been
sensitized to other similar proteins, skewing the data. While
a few individuals expressed some concern that there may be
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an instance when a FASTA or BLAST search looking for >35%
identity over 80 amino acids might miss a few cross-reactive
matches, the general opinion seemed to be that this criteria
is quite conservative and should continue to be used in the
allergenicity assessment of GE proteins.
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